Catalent Publishes Fiscal 2019 Corporate Responsibility Report
April 13 2020 - 7:44PM
Business Wire
Catalent, Inc. (NYSE: CTLT), the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene and therapies, and
consumer health products, today published its first Corporate
Responsibility (CR) Report, covering fiscal year 2019. The report
brings a new level transparency and ambition to a wide range of
environmental, social and governance (ESG) topics related to
Catalent’s business.
Catalent’s CR strategy aligns with and is an important aspect of
the company’s mission to help people live better, healthier lives.
“Responsible business practices reflect our deep commitment to our
mission and values,” said John Chiminski, Catalent’s Chair and
Chief Executive Officer. “This report communicates our CR
priorities and progress at an enterprise level, demonstrating
Catalent’s ongoing commitment to long-term value-creation and
sustainability by investing in people, the environment, and our
communities.”
In the report, Catalent shares its approach to ESG focus areas
such as product quality, safety, environmental sustainability, and
diversity and inclusion. Highlights in the report include
Catalent’s global accreditation under ISO 14001 and OHSAS 18001,
the leading environmental and occupational safety standards; the
establishment of a goal to reduce its carbon emissions by 15% by
2023 by investing in energy efficiency and renewable energy; its
launch in fiscal 2019 of additional community giving and volunteer
programs; and its enhanced commitment to cultivating an even
stronger, more inclusive workplace by signing the CEO Action for
Diversity and Inclusion pledge.
To meet the needs of investors, the report includes a discussion
of Catalent’s adherence to the Sustainability Accounting Standards
Board standard for the Biotechnology and Pharmaceuticals
sector.
The 2019 Catalent Corporate Responsibility report is available
at www.catalent.com/about-us/corporate-responsibility.
To request further information, email
CorporateResponsibility@Catalent.com.
Notes for Editors
About Catalent
Catalent, Inc. (NYSE: CTLT) is the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene therapies, and
consumer health products. With over 85 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
global clinical and commercial product supply. Catalent employs
over 13,000 people, including over 2,400 scientists and
technicians, at more than 35 facilities, and in fiscal year 2019
generated over $2.5 billion in annual revenue. Catalent is
headquartered in Somerset, New Jersey. For more information, visit
www.catalent.com.
More products. Better treatments. Reliably supplied.™
Forward-Looking Statements
In addition to historical information, this release and the
Corporate Responsibility report contain forward-looking statements,
which generally can be identified by the use of phrases such as
“will,” “intend,” anticipate,” “likely,” or other phrases with
similar meanings. Similarly, statements that describe Catalent’s
objectives, plans, or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events and actual results could vary materially from our
expectations and projections. One factor that could cause actual
results to differ are the current or future effects of the COVID-19
pandemic. For other factors that could cause actual results to
differ, see the “risk” section of our Annual Report on Form 10-K
for the fiscal year ended June 30, 2019, filed August 27, 2019 with
the U.S. Securities & Exchange Commission. All forward-looking
statements speak only as of the date of this release and the
report, respectively, and we do not undertake to update any
forward-looking statement as a result of new information or future
events except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200413005509/en/
Media: Chris Halling +44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns +44 (0) 161 728 5880 richard@nepr.agency
Investors: Paul Surdez +1 (732) 537-6505
investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Sep 2023 to Sep 2024